Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm.


OBJECTIVE To evaluate our early experience with neoadjuvant therapy (sunitinib or sorafenib) in advanced renal cell carcinoma (RCC), to explore the effect on both tumour biology and potential for downstaging advanced tumours, as systemic therapy for RCC has historically resulted in little if any primary tumour response, but recent experience with targeted… (More)
DOI: 10.1111/j.1464-410X.2008.07660.x